As public health officials deal with a second wave of the novel H1N1 influenza virus, new information is available on the health consequences of exposure to such airborne infectious diseases and the implications on the design, installation and operation of HVAC&R systems.
“While the long-standing public health view is that influenza transmission occurs through direct contact or large droplets, newer data suggests it also occurs through the airborne route, meaning HVAC&R systems may contribute far more to transmission of the disease and, potentially, to reduction of that same transmission risk,” says Gordon Holness, president of the American Society of Heating, Refrigerating and Air-Conditioning Engineering (ASHRAE) that developed the guidance.
ASHRAE’s Airborne Infectious Diseases Position Document addresses the impact of ventilation on disease transmission, the disease for which ventilation is important for either transmission or control and the control strategies that are available for implementation in buildings. The paper can be accessed at www.ashrae.org/positiondocuments.
Since the first reported case in the spring of 2009, the novel H1N1 influenza virus has spread to nearly 170 countries, resulting in 1,154 deaths and some 160,000 illnesses. With a better understanding of ventilation’s effect on the transmission of disease, future incidents of the H1N1 virus may now be easier to prevent, according to Holness. He said several technical solutions are available to assist in avoiding transmission. These include: dilution ventilation, airflow strategies, room pressurization, personalized ventilation, source control, filtration and ultraviolet germicidal irradiation.
Airborne transmission through building ventilation systems can be significantly reduced by provision of adequate air filtration and pressurization, Holness said. ASHRAE’s other guidance of relevance includes Standard 170, Ventilation of Health Care Facilities.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.